Lack of Effect of Tenofovir Disoproxil Fumarate on Pharmacokinetics of Hormonal Contraceptives
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Study Objective. To assess the potential for a drug‐drug interaction between a representative hormonal contraceptive (norgestimate‐ethinyl estradiol) and tenofovir disoproxil fumarate (tenofovir DF), a prodrug of tenofovir, when coadministered. Design. Thirty‐day, open‐label, fixed‐sequence, pharmacokinetic drug‐drug interaction study. Setting. Single clinical phase I center. Participants. Twenty nonpregnant and nonlactating women aged 19–45 years who were taking a norgestimate‐ethinyl estradiol oral contraceptive. Intervention. Each woman received norgestimate‐ethinyl estradiol alone on study days 1–22, followed by norgestimate‐ethinyl estradiol plus tenofovir DF 300 mg once/day for 7 days during two consecutive 28‐day contraceptive cycles. Measurements and Main Results. Pharmacokinetic assessments were performed over 24 hours on study days 1 and 29 (corresponding to matching days [day 21] of the two contraceptive cycles). Serum or plasma concentrations of tenofovir, norgestimate and its active metabolite deacetyl norgestimate, and ethinyl estradiol were measured by high‐performance liquid chromatography‐tandem mass spectrometry assays. Geometric mean ratios (90% confidence intervals) for the pharmacokinetic parameters for deacetyl norgestimate and ethinyl estradiol were estimated by using analysis of variance and compared with the no‐effect criterion for bioequivalence. The tenofovir pharmacokinetic parameters were compared with historical controls. Pharmacokinetic parameters for deacetyl norgestimate and ethinyl estradiol were unaltered by coadministration of tenofovir DF. The tenofovir pharmacokinetic parameters in subjects receiving norgestimate‐ethinyl estradiol were consistent with historical control data for tenofovir. Conclusion. Tenofovir DF and norgestimate‐ethinyl estradiol are not involved in a clinically significant drug‐drug interaction; tenofovir DF did not affect the steady‐state pharmacokinetics of norgestimate or ethinyl estradiol, including the concentration at the end of the dosing interval. Both drugs were well tolerated when coadministered. Tenofovir DF is unlikely to affect the pharmacokinetics of hormonal oral contraceptives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacokinetic drug interactions with oral contraceptives
Back, D. J., & Orme, M. L. (1990) · Clinical Pharmacokinetics · doi:10.2165/00003088-199018060-00004 · Cited by 209
Cited by
U.S. Medical Eligibility Criteria for Contraceptive Use, 2016
Curtis, K. M., Tepper, N. K., Jatlaoui, T. C., Berry-Bibee, E., Horton, L. G., Zapata, L. B., Simmons, K. B., Pagano, H. P., Jamieson, D. J., & Whiteman, M. K. (2016) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6503a1 · Cited by 1,456
Mayer, K. H., Molina, J.-M., Thompson, M. A., Anderson, P. L., Mounzer, K. C., De Wet, J. J., DeJesus, E., Jessen, H., Grant, R. M., Ruane, P. J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31065-5 · Cited by 428
Self-citationIntegrated and Gender-Affirming Transgender Clinical Care and Research
Reisner, S. L., Radix, A., & Deutsch, M. B. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001088 · Cited by 311
Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention
van der Straten, A., Van Damme, L., Haberer, J. E., & Bangsberg, D. R. (2012) · AIDS · doi:10.1097/qad.0b013e3283522272 · Cited by 297
HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial
Deutsch, M. B., Glidden, D. V., Sevelius, J., Keatley, J., McMahan, V., Guanira, J., Kallas, E. G., Chariyalertsak, S., & Grant, R. M. (2015) · The Lancet HIV · doi:10.1016/s2352-3018(15)00206-4 · Cited by 268
Metadata
- Authors
- Kearney, B. P., & Mathias, A.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2009-08
- Volume
- 29
- Issue
- 8
- Pages
- 924-929
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W1994036015
- Cited by
- 49
- References
- 1
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.